Emerging Pharmaceutical Market in Indonesia and Philippines - 100% Foreign Direct Investment in Indonesia and Extensive Insurance Coverage in the Philippines Attract Foreign Pharma Companies

Emerging Pharmaceutical Market in Indonesia and Philippines - 100% Foreign Direct Investment in Indonesia and Extensive Insurance Coverage in the Philippines Attract Foreign Pharma Companies

Summary

GBI Research’s new report, “Emerging Pharmaceutical Market in Indonesia and Philippines - 100% Foreign Direct Investment in Indonesia and Extensive Insurance Coverage in the Philippines Attract Foreign Pharma Companies”, provides an in-depth analysis of trends, issues and challenges in the pharmaceutical market in Indonesia and in the Philippines. The report analyzes the overall pharma market structure in these countries, provides competitive benchmarking for the leading companies, and analyzes the M&A and strategic partnerships that shape the Indonesian and Filipino pharmaceutical market. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts.

The Indonesian pharmaceutical industry exhibited high growth after the government announced a plan to allow 100% foreign ownership of drug firms to increase overseas investment in the sector and thereby raise the volume and quality of local production. The Philippines’ pharmaceutical industry on the other hand witnessed slow growth due to a drug pricing law implemented by the government. The Indonesian pharmaceutical industry has noticeably changed since the approval of the Universally Accessible Cheaper and Quality Medicines Act that includes the Maximum Drug Retail Price (MDRP) scheme. MDRP called for a 50% price reduction for more than 100 drugs.

Indonesia and the Philippines recently joined the ranks of the top 20 most populated countries in the world, meaning they offer huge patient populations. There has been a rise in the incidence of chronic diseases like diabetes, obesity, and cardiovascular disease. Emerging markets such as Indonesia must address the population’s rising demand for healthcare and significant unmet medical needs.

The Philippines’ CRO market is gaining attention globally due to its favorable regulatory environment and huge patient base offered by the country’s large population. However, the Indonesian CRO market is not as favorable for drugs registration procedures, which currently take 300 days after submission to the Indonesian Food and Drug Monitoring Agency (BPOM). Indonesia and the Philippines currently account for a tiny share of the global CMO market but are set to capitalize on increasing outsourcing opportunities from western countries.

Scope

• Overall pharma market structure in Indonesia and the Philippines
• Indonesia and the Philippines’ pharmaceutical market characterizations, including market size, major regulatory bodies, pricing and reimbursement issues, major distribution channel and intellectual property rights
• Indonesia and the Philippines’ CMO and CRO market analysis
• Analysis of the leading segments within the Indonesia and Filipino pharmaceutical industries
• Competitive benchmarking of leading companies in the pharmaceutical markets
• Key M&A activities and strategic partnership deals that have taken place between 2004 to 2011

Reasons to buy

• Develop market-entry and market expansion strategies by identifying the leading emerging markets poised for strong growth.
• Devise a more tailored country strategy through the understanding of key drivers and barriers of the country’s pharmaceutical market.
• Develop key strategic initiatives by understanding the key focus areas of leading companies.
• Accelerate and strengthen your market position by identifying key companies for mergers, acquisitions and strategic partnerships.